Laurus Labs Q3 net slides 43% as ARV sales drag

Drugmaker post ₹154.97 cr consolidated net profit

January 27, 2022 10:42 pm | Updated 10:42 pm IST - Hyderabad

Drugmaker Laurus Labs reported a more than 43% decline in consolidated net profit to ₹154.97 crore for the quarter ended December 31, 2021.

The lower net profit, compared with the ₹272.85 crore seen a year earlier, came on the back of total income of ₹1,034.09 crore (₹1,295.35 crore). The company attributed the 20% decline in income to the transient inventory correction of the anti-retroviral (ARV) business.

Core results continued to remain resilient with strong growth in synthesis and other APIs, Laurus said in a release. CEO Satyanarayana Chava said lower sales of ARV APIs and formulations due to stocking at channel partners had affected Q3 results.

Top News Today

Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in


Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.